Clinical Trials Logo

Filter by:
NCT ID: NCT04382547 Completed - Covid-19 Clinical Trials

Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells

Start date: May 11, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

NCT ID: NCT04327037 Completed - Clinical trials for Leukemia, Acute Lymphoblastic

Safety of Expanded Haploidentical Natural Killer Cells for Leukemia

Start date: January 2, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the safety of ex vivo expanded haploidentical natural killer (NK) cells for patients with leukemia.

NCT ID: NCT04207112 Completed - Clinical trials for Multi-drug Resistant Tuberculosis

Economic Evaluation of New MDR TB Regimens

PRACTECAL-EE
Start date: October 20, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The current treatment regimen for MDR-TB has poor outcomes and costs of treating MDR-TB are greater than treating drug susceptible TB, both in terms of health service and patient-incurred costs. Urgent action is needed to Identify short, effective and tolerable treatments for people with MDR-TB. The PRACTECAL economic evaluation sub-study (PRACTECAL-EE) will take place alongside the TB PRACTECAL trial, aiming to assess the costs to patients and providers of such regimens and to estimate the cost-effectiveness and poverty impact of an introduction of new MDR-TB regimens in the three countries participating in the main study.

NCT ID: NCT04184258 Completed - Clinical trials for Systemic Lupus Erythematosus

Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells

Start date: July 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of systemic lupus erythematosus with pooled allogenic mesenchymal stem cells

NCT ID: NCT04184232 Completed - Bladder Cancer Clinical Trials

Treatment of Recurrent Bladder Cancer With Dendritic Cells

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

Treatment of recurrent bladder cancer with dendritic cells

NCT ID: NCT04121221 Completed - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot, a long acting IM injection of glatiramer acetate, administered once every four weeks

NCT ID: NCT04115488 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis (RRMS)

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Antelope
Start date: October 1, 2019
Phase: Phase 3
Study type: Interventional

This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks. Approximately 260 participants with relapsing-remitting multiple sclerosis will be randomized to receive 12 doses of either PB006 or EU-licensed Natalizumab.

NCT ID: NCT04109391 Completed - Breast Cancer Clinical Trials

Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

Start date: August 20, 2019
Phase: Phase 3
Study type: Interventional

This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.

NCT ID: NCT04096729 Completed - Clinical trials for Patient Satisfaction

Patients Commitment to Compression Therapy

POMP
Start date: October 1, 2019
Phase:
Study type: Observational

The study Patients Commitment to compression therapy (POMP) is observational, prospective. After the Phlebologist consultation after 1 month and 1 year, a telephone questionnaire is carried out for the patients included in the study with the involvement of a company specializing in conducting a telephone questionnaire. Patients will be interviewed about the implementation of the doctor's recommendations regarding compression therapy over a period 1 month and 1 year.

NCT ID: NCT04053699 Completed - Clinical trials for Von Willebrand Diseases

Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment

Start date: June 25, 2019
Phase:
Study type: Observational

The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months. The data obtained will be used as a basis for historical comparisons with the bleeding and treatment pattern obtained from a clinical study on the efficacy of prophylactic treatment with a VWF/FVIII concentrate.